Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous antibiotic infusion in children
2025-522809-38-00Phase 3Authorised
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Feb 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of cloxacillin, benzylpenicillin and piperacillin + tazobactam in bacterial disease, sponsored by Pirkanmaan hyvinvointialue. Primary endpoints: Duration of hospital stay, Duration of fever and 3 more. Planned start Feb 2026; status: authorised.
02
Drugs
cloxacillinbenzylpenicillinpiperacillin + tazobactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2025-522809-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522809-38-00.